Overall, our findings suggest that adjuvant immunotherapy improves DFS in patients with resected NSCLC, particularly in those who are EGFR-negative, have PD-L1 expression of 1–49%, have non-squamous cell carcinoma, and have never smoked. Here, CD274 is linked to squamous cell carcinoma.